Mirdametinib approval for neurofibromatosis type 1 with inoperable plexiform neurofibromas: the journey of MEK inhibitors
Open Access
- 8 May 2025
- journal article
- Published by Elsevier in ESMO Rare Cancers
- Vol. 3
Abstract
No abstract availableThis publication has 11 references indexed in Scilit:
- ReNeu: A Pivotal, Phase IIb Trial of Mirdametinib in Adults and Children With Symptomatic Neurofibromatosis Type 1-Associated Plexiform NeurofibromaJournal of Clinical Oncology, 2025
- Incidence and prevalence of neurofibromatosis type 1 and 2: a systematic review and meta-analysisOrphanet Journal of Rare Diseases, 2023
- Dynamic regulation of RAS and RAS signalingBiochemical Journal, 2023
- Neurofibroma Development in Neurofibromatosis Type 1: Insights from Cellular Origin and Schwann Cell Lineage DevelopmentCancers, 2022
- Management of neurofibromatosis type 1-associated plexiform neurofibromasNeuro-Oncology, 2022
- NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasJournal of Clinical Oncology, 2021
- Plexiform neurofibroma with neurofibromatosis type I/ von Recklinghausen's disease: A rare case reportAnnals of Medicine & Surgery, 2020
- Selumetinib in Children with Inoperable Plexiform NeurofibromasNew England Journal of Medicine, 2020
- Phenotype categorization of neurofibromatosis type I and correlation to NF1 mutation typesJournal of Human Genetics, 2019
- Neurofibromatosis type 1: a multidisciplinary approach to careThe Lancet Neurology, 2014